Mirion Technologies and Westinghouse Partner to Drive Digital Innovation in Nuclear Instrumentation Systems
Mirion Technologies (NYSE: MIR), a leading provider of advanced radiation safety solutions, and Westinghouse Electric Company LLC, a leading supplier of nuclear plant instrumentation and control systems, have announced a strategic partnership to provide digital Ex-core Nuclear Instrumentation Systems (NIS) based on the high-performing Mirion proTK product line. This collaboration aims to alleviate operator and maintenance burdens, enhance performance, and ensure sustained operation success. This digital NIS upgrade solution is offered exclusively through Westinghouse for both Westinghouse and Combustion Engineering designed PWRs worldwide.
This initiative leverages Mirion’s proTK product line to upgrade existing analog neutron flux monitoring drawers, which were originally designed in the 1960s, to a state-of-the-art digital system. The Mirion proTK product line represents an advanced and reliable Ex-core neutron flux measurement solution to replace the outdated equipment that can be costly and labor-intensive to maintain. Additionally, the Westinghouse and Mirion collaboration provides a drop-in replacement for legacy systems, minimizing disruptions to operations and training. With over 400 drawers implemented globally, reflecting more than 4000 operating years, Mirion’s proTK product line has a proven track record for reliability and performance in nuclear facilities of any size and complexity.
“At Mirion, we are committed to advancing the nuclear industry through proven radiation safety technologies and expertise, and this partnership with Westinghouse underscores the importance of digital innovation.” said Loic Eloy, President of Mirion Technologies Group. “The integration of our proTK technology into the Westinghouse-designed fleet will bring unparallelled reliability and accuracy. We are excited to support the long-term success of the Westinghouse nuclear footprint through this initiative.”
For more information about Westinghouse and this digital NIS upgrade offering, please visit westinghousenuclear.com.
To learn more about Mirion’s proTK product line, visit mirion.com.
About Mirion
Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. Focused on nuclear and safety, the Mirion Technologies group is committed to powering advancements in nuclear energy through proven radiation safety technologies and expertise. Dedicated to driving better patient outcomes, the Mirion Medical group is focused on improving quality in cancer care through its broad range of solutions that enhance the delivery and ensure safety across the medical landscape. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,800 people and operates in 12 countries. Learn more at https://www.mirion.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250624849892/en/
Contacts
For investor inquiries:
Eric Linn
ir@mirion.com
For media inquiries:
Erin Schesny
media@mirion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces New Assignments of Directors25.6.2025 10:07:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs. Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company’s values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success. Details of the new assignments are as follows: 1. New Assignment of Directors Who Are Not Audit and Supervis
Anew Climate and Aurora Sustainable Lands Collaborate with Microsoft to Deliver Landmark 10-Year Agreement for Carbon Removal Credits25.6.2025 10:00:00 EEST | Press release
Anew Climate and Aurora Sustainable Lands today announced a 10-year agreement with Microsoft to deliver 4.8 million nature-based carbon removal credits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625732509/en/ The deal supports one of the largest permanent working forest carbon removal efforts in the United States, and will provide investments and jobs across timberland communities. The projects, developed by Anew Climate and owned and managed by Aurora Sustainable Lands, span ecologically diverse forestlands in New York, Virginia, West Virginia, Kentucky, and Florida and utilize Improved Forest Management (IFM) to generate nature-based removal credits. Removals from these projects will be among the first issued under ACR’s IFM v2.1 protocol, a next-generation methodology that advances the field via dynamic baselines, enhanced additionality and monitoring requirements, improved quantification accuracy, and increased t
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin25.6.2025 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need.1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc.1,3,4 “Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these sever
MSCI Announces Results of the MSCI 2025 Market Classification Review25.6.2025 00:55:00 EEST | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today the results of the MSCI 2025 Market Classification Review. Select highlights of this year’s review includes MSCI: Extending the consultation on a potential reclassification of Bulgaria from Standalone to Frontier Market status Continuing to monitor the implementation and market adoption of measures to enhance the accessibility of the Korean equity market, to determine whether these measures have replicated the outcomes of fully operational offshore FX markets such as those found in Developed Markets Providing updates on the market classification status of Greece Continuing to monitor the market accessibility of the Bangladesh equity market “MSCI is committed to ensuring that our market classifications reflect the evolving realities of global accessibility and investability,” said Raman Aylur Subramanian, Head of Index R&D. “In 2025, we have see
Jørgen Vig Knudstorp Nominated to Join NIKE, Inc. Board of Directors24.6.2025 23:15:00 EEST | Press release
NIKE, Inc. (NYSE:NKE) today announced Jørgen Vig Knudstorp has been nominated for election to its Board of Directors at the Company’s 2025 annual meeting of shareholders, to be held on September 9, 2025. Mr. Knudstorp was President and Chief Executive Officer of the LEGO Group (“LEGO”) from 2004 to 2016, Executive Chair of LEGO Brand Group from 2017 to 2023 and currently serves as Deputy Chair of the LEGO Foundation. He previously held various leadership positions at LEGO from 2001 to 2004. “Jørgen’s strong global experience with brand and digital marketing, strategy, and consumer products, as well as his development and fostering of culture and values, will make him an excellent addition to our board,” said Mark Parker, Executive Chairman of NIKE, Inc. “We look forward to working with Jørgen during an exciting time for NIKE where we will unlock our next chapter of growth through innovative product and distinctive brand storytelling across an integrated marketplace.” Prior to joining L
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom